Delivery Order SPE2DB24D1021-SPE2DB25FEXGC
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Esbriet 801 mg tablets (90-count units) with a contract ceiling value of $3,425.95. This non-set-aside, competitively awarded delivery order carries firm fixed pricing and is scheduled for completion by June 3, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued under...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Esbriet 801 mg tablets (90-count units) on August 18, 2025, with completion targeted for September 9, 2025. This non-set-aside competitive award is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $1 billion...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $3,425.95 delivery order on August 13, 2025, for 270 tablets of Esbriet 267 mg, a pulmonary fibrosis medication. This competitively awarded, firm fixed-price contract contains no set-aside designation and is scheduled for completion by September 4, 2025. The pharmaceutical supply will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Esbriet (pirfenidone) 801 mg tablets in a 90-count quantity. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 13, 2025, and performance location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply contract vehicle with DLA, enabling the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Esbriet 801 mg tablets (90-count units) with a ceiling value of $3,425.95. This firm fixed-price delivery order, issued on September 10, 2025, is scheduled for completion by October 1, 2025, and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting the contractor's established...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for supply of ESBRIET 801 mg tablets (90-count). This contract represents a non-set-aside, competitively awarded delivery order with performance expected in Conshohocken, Pennsylvania, and an ultimate completion date of June 23, 2025. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp on June 27, 2025, for 90 tablets of Esbriet 801 mg, a pharmaceutical treatment for idiopathic pulmonary fibrosis. This firm fixed-price delivery order, with an ultimate completion date of July 21, 2025, was competitively awarded without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Esbriet 801 mg tablets (90-count) with a completion date of October 6, 2025. This is a firm fixed price, non-set-aside contract performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed price delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, a pharmaceutical product used in the treatment of idiopathic pulmonary fibrosis. This non-set-aside competitive award was issued on June 16, 2025, with an ultimate completion date of July 9, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract action...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Esbriet 267 mg tablets (270-count packages) at a firm fixed price of $3,425.95, with completion scheduled for September 30, 2025. This is a non-set-aside competitive award issued as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FEXGCDelivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $3,425.95 for 90 tablets of Esbriet 801 mg, with a completion date of June 24, 2025. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The place of performance is located at AmerisourceBergen's corporate office in Conshohocken. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 and runs through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including medications, vaccines, and specialized medical commodities across multiple therapeutic domains. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen has demonstrated capability to meet DLA requirements through open competition on numerous prior contract awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 6/2/25 |